X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Elder Pharma with GSK Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs GSK PHARMA - Comparison Results

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA GSK PHARMA ELDER PHARMA/
GSK PHARMA
 
P/E (TTM) x -0.2 62.8 - View Chart
P/BV x 0.1 10.1 1.0% View Chart
Dividend Yield % 0.0 1.3 -  

Financials

 ELDER PHARMA   GSK PHARMA
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
GSK PHARMA
Mar-17
ELDER PHARMA/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs3803,838 9.9%   
Low Rs1882,637 7.1%   
Sales per share (Unadj.) Rs491.2354.2 138.7%  
Earnings per share (Unadj.) Rs-3.239.8 -8.0%  
Cash flow per share (Unadj.) Rs14.442.9 33.6%  
Dividends per share (Unadj.) Rs030.00 0.0%  
Dividend yield (eoy) %00.9 0.0%  
Book value per share (Unadj.) Rs376.5236.9 158.9%  
Shares outstanding (eoy) m20.5484.70 24.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.69.1 6.3%   
Avg P/E ratio x-89.381.4 -109.6%  
P/CF ratio (eoy) x19.775.5 26.1%  
Price / Book Value ratio x0.813.7 5.5%  
Dividend payout %075.4 0.0%   
Avg Mkt Cap Rs m5,833274,216 2.1%   
No. of employees `000NA4.7 0.0%   
Total wages/salary Rs m2,1794,830 45.1%   
Avg. sales/employee Rs ThNM6,387.0-  
Avg. wages/employee Rs ThNM1,028.3-  
Avg. net profit/employee Rs ThNM717.1-  
INCOME DATA
Net Sales Rs m10,08930,000 33.6%  
Other income Rs m257728 35.2%   
Total revenues Rs m10,34630,728 33.7%   
Gross profit Rs m-7924,190 -18.9%  
Depreciation Rs m361263 137.4%   
Interest Rs m2,7560-   
Profit before tax Rs m-3,6534,655 -78.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m3,713457 812.4%   
Tax Rs m1251,744 7.2%   
Profit after tax Rs m-653,368 -1.9%  
Gross profit margin %-7.814.0 -56.2%  
Effective tax rate %-3.437.5 -9.1%   
Net profit margin %-0.611.2 -5.8%  
BALANCE SHEET DATA
Current assets Rs m9,24016,742 55.2%   
Current liabilities Rs m9,9987,202 138.8%   
Net working cap to sales %-7.531.8 -23.6%  
Current ratio x0.92.3 39.8%  
Inventory Days Days4652 89.4%  
Debtors Days Days6021 288.4%  
Net fixed assets Rs m10,1248,635 117.2%   
Share capital Rs m206847 24.3%   
"Free" reserves Rs m5,58219,222 29.0%   
Net worth Rs m7,73420,069 38.5%   
Long term debt Rs m4,88910 48,890.0%   
Total assets Rs m22,88230,038 76.2%  
Interest coverage x-0.3NM-  
Debt to equity ratio x0.60 126,870.4%  
Sales to assets ratio x0.41.0 44.1%   
Return on assets %11.811.2 104.9%  
Return on equity %-0.816.8 -5.0%  
Return on capital %22.325.5 87.6%  
Exports to sales %3.00-   
Imports to sales %0.40-   
Exports (fob) Rs m307NA-   
Imports (cif) Rs m43NA-   
Fx inflow Rs m307528 58.1%   
Fx outflow Rs m1257,193 1.7%   
Net fx Rs m181-6,665 -2.7%   
CASH FLOW
From Operations Rs m11,7542,360 498.1%  
From Investments Rs m-5613,008 -18.6%  
From Financial Activity Rs m-6,762-5,108 132.4%  
Net Cashflow Rs m4,432260 1,702.5%  

Share Holding

Indian Promoters % 39.6 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 7.5 10.2 73.5%  
FIIs % 16.8 23.8 70.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 15.4 234.4%  
Shareholders   16,479 102,036 16.2%  
Pledged promoter(s) holding % 77.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   PANACEA BIOTECH  DISHMAN PHARMA  J.B.CHEMICALS  NATCO PHARMA  DIVIS LABORATORIES  

Compare ELDER PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Firm; Healthcare & Metal Stocks Gain(09:30 am)

Asian stocks are higher today as Chinese and Hong Kong shares show gains. The Shanghai Composite is up 0.17% while the Hang Seng is up 0.95%. The Nikkei 225 is trading up by 0.4%.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA 8-QTR ANALYSIS

COMPARE ELDER PHARMA WITH

MARKET STATS